- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic drug monitoring of 5-fluorouracil
Authors
Keywords
Capecitabine, Body Surface Area, Dose Adjustment, Therapeutic Drug Monitoring, mCRC Patient
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 3, Pages 447-464
Publisher
Springer Nature
Online
2016-05-24
DOI
10.1007/s00280-016-3054-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.
- (2017) M. J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.
- (2017) David Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy
- (2016) Maurice C. van Staveren et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Upfront Genotyping ofDPYD*2Ato Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
- (2016) Maarten J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer.
- (2015) I Peng Thomas Soh et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
- (2015) Volker Kunzmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2015) Shom Goel et al. JOURNAL OF CLINICAL ONCOLOGY
- TranslatingDPYDgenotype into DPD phenotype: using theDPYDgene activity score
- (2015) Linda M Henricks et al. PHARMACOGENOMICS
- Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer
- (2014) Daniel A. Goldstein et al. Clinical Colorectal Cancer
- Therapeutic drug monitoring in cancer – Are we missing a trick?
- (2014) Christophe Bardin et al. EUROPEAN JOURNAL OF CANCER
- Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis
- (2014) Daiana Renck et al. INVESTIGATIONAL NEW DRUGS
- Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio
- (2014) Johanna Sistonen et al. PHARMACOGENOMICS
- Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5–Fluorouracil-Based Chemotherapy Regimens
- (2013) Christina Leah B. Kline et al. Clinical Colorectal Cancer
- Pharmacokinetically Guided Dose Adjustment of 5-FU—A Critical Element Toward Personalized Medicine
- (2013) Gaurav Goel et al. Clinical Colorectal Cancer
- Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care
- (2013) J H Beumer CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients
- (2013) André BP van Kuilenburg et al. PHARMACOGENOMICS
- Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency
- (2013) M C van Staveren et al. PHARMACOGENOMICS JOURNAL
- Cost-Effectiveness Of Pharmacokinetic Dosing Of 5-Fluorouracil In Metastatic Colorectal Cancer In The United Kingdom
- (2013) R. Becker et al. VALUE IN HEALTH
- Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study
- (2012) Olivier Capitain et al. Clinical Colorectal Cancer
- Body-Surface Area–Based Chemotherapy Dosing: Appropriate in the 21st Century?
- (2012) Jan H. Beumer et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6
- (2012) R. R. Kaldate et al. ONCOLOGIST
- Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients
- (2011) Christina Leah Kline et al. CANCER BIOLOGY & THERAPY
- Body Surface Area–based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens
- (2011) Jennifer Saam et al. Clinical Colorectal Cancer
- Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity
- (2011) D. Cao et al. MOLECULAR CANCER THERAPEUTICS
- A review of analytical methods for the determination of 5-fluorouracil in biological matrices
- (2010) Massimo Breda et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
- (2010) Michel Ducreux et al. INTERNATIONAL JOURNAL OF CANCER
- Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer
- (2009) Edward Chu et al. CANCER
- Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
- (2009) M. Wasif Saif et al. JNCI-Journal of the National Cancer Institute
- Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal Cancer
- (2009) Edward Chu et al. ONCOLOGY
- Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan
- (2009) Takeru Shiroiwa et al. PHARMACOECONOMICS
- 13C-5-FU breath test current status and future directions: a comprehensive review
- (2009) Hany H Ezzeldin et al. Journal of Breath Research
- Pharmacoeconomic Benefits of Capecitabine-Based Chemotherapy in Metastatic Colorectal Cancer
- (2008) Edward Chu et al. JOURNAL OF CLINICAL ONCOLOGY
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now